Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis

摘要

Purpose:Oral mucositis is a significant toxicity of cytotoxic chemo- and radiation-therapy used to treat cancer. Palifermin is the first pharmaceutical/biological agent approved for the intervention of oral mucositis. The major objective of this review is to evaluate the evidence supporting the use of palifermin.